Genzyme wins regulatory approval in Europe of its second drug to treat multiple sclerosis

Posted: Published on September 18th, 2013

This post was added by Dr Simmons

By Robert Weisman / Globe Staff/ September 17, 2013

European regulators Tuesday put their stamp of approval on Genzymes multiple sclerosis drug candidate Lemtrada, giving the Cambridge biotechnology company its second MS treatment on the market in the European Union only weeks after it was first approved there.

The move vindicated French drug maker Sanofi SAs decision to pay $20.1 billion for Genzyme in 2011, a deal that hinged on the potential of Lemtrada, then an experimental therapy.

While it has not yet been approved for sale in the United States the Food and Drug Administration is expected to rule on Genzymes application by the end of the year Lemtrada won the European Commissions blessing both for patients who have taken other MS drugs as well as newly diagnosed patients. Full story for BostonGlobe.com subscribers.

Copyright 2013 Globe Newspaper Company.

Get the full story with unlimited access to BostonGlobe.com. Just 99 for 4 weeks.

Get Access Now

View original post here:
Genzyme wins regulatory approval in Europe of its second drug to treat multiple sclerosis

Related Posts
This entry was posted in MS Treatment. Bookmark the permalink.

Comments are closed.